ACCELERATE: A Multisite Study of a Simplified Accelerated ART Start Protocol for People With HIV Who Are Out of Care

What this Trial Is About

Researchers are evaluating the ACCELERATE model of care to help people with HIV who are out of care achieve viral suppression by Week 24. This study focuses on a simplified approach that includes outreach, telehealth access to an HIV provider, a pre-approved HIV treatment regimen, and a free 30-day medication starter pack. The study also examines how acceptable, appropriate, feasible, and sustainable this model is for both patients and staff. The ACCELERATE model starts with the study team establishing contact and providing a telehealth appointment with an HIV care provider within 24 business hours. Eligible participants are enrolled and prescribed bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which is mailed as a free 30-day starter pack. Follow-up calls occur within 2 to 4 weeks to check for side effects and adherence. Patients are then connected to an HIV clinic for ongoing care within 4 weeks, where lab tests may be performed as needed. Participants will have various assessments including monitoring HIV viral load at Week 24 to measure viral suppression. The study also tracks patient and staff experiences, satisfaction, quality of life, retention in care, and adherence over one year. Data on staff workload and burnout will be collected. Participants can expect regular evaluations, telephone follow-ups, and lab tests during their participation, which lasts at least 24 weeks with ongoing observation up to one year.

Accelerated ART Initiation for PWHIV Who Are Out of Care